Clinical trial
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or…
NCT00174252 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00174252 |
|---|---|
| Title | Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age |
| Official title | Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fetal Growth Retardation |
| Intervention type | Drug |
| Interventions | Genotonorm (Somatropin) |
| Enrollment | 57 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Jun 15, 2010 |
| Countries | France |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: